Organoid Science announced on the 9th that it has opened the "Onyx Bio Foundry AMC" at the Convergence Research Institute of the Asan Institute for Life Sciences at Seoul Asan Medical Center and will begin full-scale operations.
The Onyx Bio Foundry AMC serves as the core hub for Organoid Science's hospital-based Contract Research, Development, and Manufacturing Organization (CRDMO) platform, supporting clinical research in compliance with relevant regulations including the Advanced Biopharmaceuticals Act. By establishing the facility inside a hospital at the frontline of patient care, researchers can directly produce cell-based therapeutics in research or clinical-grade forms while consulting with medical staff in real time to rapidly adjust development strategies. The system optimizes translational research processes by quickly connecting laboratory-level data to clinical stages. It is designed as an optimal system for rapid advanced biopharmaceutical development through synergies with existing manufacturing centers.
Organoid Science plans to leverage the facility to maximize joint research and technical collaboration with hospital researchers, leading the field of organoid and cell-based precision medicine.
The opening ceremony held on the 6th was attended by key officials from both organizations, including Park Seung-il, President of Seoul Asan Medical Center; Kim Tae-won, Director of the Asan Institute for Life Sciences; Shin Dong-myung, Director of the Cell Therapy Center; and Oh Sang-hoon, CEO of Organoid Science.
Oh Sang-hoon, CEO of Organoid Science, stated, "Establishing a therapeutic production facility within Seoul Asan Medical Center, which possesses world-class clinical capabilities, is a precious milestone in drug development that organically connects research and clinical medicine," adding, "The clinical outcomes generated from this optimal system will serve as a driving force to enhance the global competitiveness of Korea's advanced bio industry alongside new drug development."